Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02926872 · ClinicalTrials.gov registry record
Screening for Lysosomal Acid Lipase Deficiency
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 22
- Enrollment target
NCT02926872 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02926872 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The primary outcome of this study is the development of a clinical profile of pediatric patients with LAL-D, which will enable the Sponsor to provide more focused guidance to the medical community as to which pediatric patients should be tested for LAL-D.
Interventions
- OTHER There is no intervention in the study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-06-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02926872
The ClinicalTrials.gov registry entry for NCT02926872 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which There is no intervention in the study is the first listed.
NCT02926872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02926872 about?
NCT02926872 is a clinical study titled "Screening for Lysosomal Acid Lipase Deficiency". The primary outcome of this study is the development of a clinical profile of pediatric patients with LAL-D, which will enable the Sponsor to provide more focused guidance to the medical community as to which pediatric patients should be tested for LAL-D.
What is the current status of trial NCT02926872?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2016-11. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT02926872?
The interventions under investigation include: There is no intervention in the study (OTHER).
Who is sponsoring clinical trial NCT02926872?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.